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As one of the most prevalent functional gastrointestinal disorders (FGIDs), irritable bowel 
syndrome (IBS) affects more than 10% of the general population worldwide with a higher 
prevalence in women. The primary clinical manifestation of IBS is chronic abdominal pain or 
discomfort associated with changes in stool frequency and appearance. IBS is the second 
leading cause of work absenteeism after colds and has remarkable effects on the socio-
economic system. The pathophysiology of IBS has not been fully clarified yet, including 
various peripheral and central mechanisms. 
From the late 1980s, genetic predisposition to IBS has been demonstrated by family and twin 
studies. Several candidate genes have been linked to IBS susceptibility including TNFSF15, 
NPSR1, SCN5A, TRPM8, and SI. Moreover, a few underpowered genome-wide association 
studies (GWAS) have been performed to investigate IBS genetics in population-based 
cohorts. However, to date, no unequivocal genetic factor has been confirmed yet.  
In this thesis, we aim to identify risk genes and variants associated with IBS and to 
characterize their functional roles. The first part focuses on the role of genetic variations in 
the sucrase-isomaltase (SI) gene and IBS susceptibility. In the second part, the hypothesis-
free GWAS approaches are implemented to detect IBS risk genes and variants in large-scale 
powered cohorts.  
In Paper I, we have exploited a two-step computational strategy to study the prevalence of SI 
rare pathogenic variants (SI-RPVs) in 2207 tertiary IBS patients. The prevalence of selected 
SI-RPVs in all IBS patients is 3.99%, which is significantly higher than the reference 
population (P=0.00049). This study has provided supporting evidence that links carrying SI-
RPVs to increased risk of IBS.  
Paper II has investigated the effects of SI functional variants in the response to dietary 
intervention in IBS patients. The genotypes of SI hypomorphic variants were obtained for a 
group of IBS-D patients previously treated with a low FODMAP diet in a clinical trial. After 
stratifying IBS patients into carriers and non-carriers of SI hypomorphic variants, we have 
observed significantly lower efficiency of low FODMAP diet in carriers compared to non-
carriers (P=0.031). These findings suggest that SI genotype data may contribute to identifying 
individuals with higher chances to benefit from such dietary interventions.  
In Paper III, we have performed a GWAS of self-reported IBS exploiting the large 
population-based UK Biobank. After quality control, the association analysis has been carried 
out in 9,576 IBS patients and 336,499 controls via logistic regression. Genome-wide 
significant signals have been identified on chromosome 9q31.2, and sex-stratified analysis 
suggests this locus is female-specific. This finding has been further supported by replication 
evidence from analyses in a pooled cohort with multi-national tertiary IBS cases and controls 
and a Swedish population-based cohort. 
In the end, IBS GWAS and their meta-analyses have been performed in large-scale multi-
national tertiary IBS cases and controls from European countries and the US in Paper IV. 
We have identified two novel genome-wide significant loci in IBS-D meta-analyses, and the 
results from functional annotation and PheWAS screening have suggested the association of 
these loci with altered metabolic and immune activities as well as psychiatric conditions. Ion 
channel biology was also highlighted as plausible pathways linked to IBS. 
Taken together, this thesis has provided new insight that improves current understanding of 
genetic predisposition to IBS. In the long run, the discovery of IBS predisposing genes and 
variants may have a significant impact on IBS management, since it is expected to allow 
patients stratification and therefore increase the specificity and efficacy of treatment. 
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1 BACKGROUND 
1.1 FUNCTIONAL GASTROINTESTINAL DISORDERS 
The functional gastrointestinal disorders (FGIDs) are described as a heterogeneous group of 
chronic functional conditions of the gastrointestinal (GI) system, as their symptoms manifest 
in the absence of identifiable structural or biochemical abnormalities.(1,2) The term 
"functional" generally refers to abnormal activities in the body such as changes in gut motility 
or visceral hypersensitivity. However, negative (non-disease) results are usually obtained 
from routine serological, imaging and endoscopic examinations.  
The definition of FGIDs has been changing over time, from non-organic diseases, psychiatric 
comorbidities to disorders of gut-brain interaction.(1) They encompass disorders with 
symptoms related to GI motility, visceral hypersensitivity, altered immune activities, 
dysbiosis, and changes in the central nervous system processing.(2) Recent studies have 
proposed that the FGIDs phenotypes result from the complex interactions between genetic, 
environmental, psychological and physiological factors.(3,4) The pathophysiology of FGIDs 
is illustrated in a biopsychosocial model as shown in Figure 1. 
FGIDs are the most common reasons for referral to a gastroenterologist worldwide, and many 
people do not consult a physician for their GI symptoms.(5) Despite the high prevalence, the 
etiology of FGIDs has not been clarified yet. To date, diagnosis and classification of FGIDs 
are established based on patients’ symptoms. The current most widely accepted diagnostic 
criteria for FGIDs are from Rome Foundation. Since the late 1980s, expert researchers and 
clinicians worldwide have gathered and assessed the characteristics, diagnostic and the 
therapeutic aspects of FGIDs. The Rome Foundation was set up in 1996, and since then, the 
foundation has played a key role in FGIDs research work.(1,2) Their collaborations have 
resulted in the criteria in FGIDs diagnosis, the so-called “Rome Criteria.” The latest Rome IV 
criteria comprise 33 adult and 20 pediatric FGIDs, which are classified into eight domains 
according to their anatomic locations.(2) A detailed list of adult FGIDs in Rome IV 
classification is shown in Figure 1. Nevertheless, the Rome IV criteria have just been 
released and not widely utilized yet in scientific literatures. Rome III criteria are still “golden 
standards” in most FGIDs studies and are what we refer to in this thesis.  
There are limitations to the application of Rome Criteria in clinical settings. First, the 
symptom-based criteria categorize individuals into patients and non-patient groups. Those 
who have similar symptoms are excluded if they do not fully meet the criteria. Second, Rome 
Criteria weight more on patients’ symptoms, while other dimensions of the patients’ 
 2 
conditions (e.g., psychosocial, quality of life) are not fully taken into consideration. 
Therefore, a more integrated profile should be added to patients’ clinical manifestation when 
using Rome Criteria in clinical cares. Despite the limitations, Rome Criteria are still valuable 
instruments for research proposes.  
 
FIGURE 1. A biopsychosocial model for the conceptualization of FGIDs pathophysiology 
and Rome IV classification.  
 
1.2 IRRITABLE BOWEL SYNDROME 
1.2.1 Clinical characteristics 
Irritable bowel syndrome (IBS) is one of FGIDs with high population prevalence, with main 
clinical manifestations of chronic abdominal pain associated with bloating, gas, constipation 
or diarrhea.(6) IBS is defined as recurrent abdominal pain or discomfort (more than 3 
days/month in >3 months) based on Rome III criteria, together with at least two 
accompanying symptoms: 1) symptom remission after defecation, 2) symptom onset links to 
changes in bowel movements, 3) symptom onset associated with stool form changes.(1) 
Specific subtypes of IBS are established on patients’ bowel habits and the predominant 
pattern, including IBS-D (diarrhea), IBS-C (constipation), IBS-M (alternating diarrhea and 
constipation) or IBS-U (unclassified), as described in Figure 2. Given that IBS symptoms 
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can also be present in other GI diseases (primarily inflammatory bowel diseases and celiac 
disease), IBS often remains a diagnosis of exclusion in routine clinical practice. 
 
FIGURE 2. A two-dimensional figure illustrates the definition of IBS subtypes. According to 
the frequency of lumpy and watery stools, IBS patients can be classified into four subgroups: 
IBS-D (diarrhea), IBS-C (constipation), IBS-M (alternating diarrhea and constipation) or 
IBS-U (unclassified). Reprinted with permission from Enck, P. et al., Nat Rev Dis Primers. 
2016 Mar 24;2:16014. Copyright © 2016, Springer Nature. 
 
Although IBS is not a life-threatening condition, it seriously impacts patients’ quality of life 
and has significant impacts on the health and socio-economic system. As a chronic condition, 
IBS symptoms affect many patients for more than ten years,(7) hence IBS accounts for a 
large proportion of primary care and gastroenterology practice.(8,9) As the second leading 
cause of work absenteeism after colds, IBS costs translate approximately into 1600 Euros per 
patient per year, for an estimated 0.5% of the annual national healthcare budget in the 
US.(10) 
1.2.2 Epidemiology of IBS 
The prevalence of IBS ranges between 10% and 25% in individual community 
surveys,(8,11–17) Figure 3 shows the detailed population IBS prevalence worldwide.(18) A 
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meta-analysis has demonstrated a global IBS prevalence of 11.2% (95% CI: 9.8–
12.8),(19,20) while another recent literature review from the Rome Foundation working team 
described a significant degree of heterogeneity of IBS prevalence among different countries, 
ranging from 5.8% in the Middle East/Africa to 17.5% in Latin America.(21) The 
epidemiological data from most African countries and many Asian countries are not yet 
available, which may attribute to the inadequate attention paid to functional disorders. On the 
other hand, it is also noteworthy that the reported IBS prevalence in some developing 
countries is higher than developed countries, this may be due to the poorer life condition and 
a higher incidence of infectious diarrhea (mainly in tropical countries), their milder types 
could be misdiagnosed as IBS.    
 
FIGURE 3. IBS prevalence in population studies around the world. Reprinted with 
permission from Enck, P. et al., Nat Rev Dis Primers. 2016 Mar 24;2:16014. Copyright © 
2016, Springer Nature. 
 
A few factors have been demonstrated to be associated with IBS, including sex, age, 
socioeconomic status, and family clustering. In most studies, IBS rates were reported to be 
higher in women than men,(9) and a meta-analysis estimated a 67% increase of odds in 
females.(20) While the specific mechanisms accounting for sex differences in IBS remain to 
be fully understood. Individuals from all age groups can be affected by IBS. Pooled analyses 
showed that IBS prevalence decreased with increasing age, especially in the age group above 
50 years’ old, but none of the difference was statistically significant.(20,22) Another study 
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revealed milder abdominal pain in older IBS patients, but worse quality of life was found 
compared with younger groups.(23) Some studies have reported IBS is more frequent in 
individuals with lower socioeconomic status,(13) although other independent studies failed in 
replicating this observation. Increased risk of IBS has been reported in individuals with a 
family history.(24,25) Genetic, environmental factors, as well as social learning, have been 
considered to play a role in the IBS family aggregations. The genetic predisposition of IBS 
will be discussed in detail in Section 1.3. 
Recent studies have demonstrated the association between GI infections and IBS. The 
estimated odds ratio for developing IBS is 5.86 (95% CI: 3.60–9.54) in individuals after their 
gastroenteritis,(26) The mechanism of post-infectious IBS is not yet clarified, low-grade 
intestinal inflammation and increased infiltration of mast cells may involve in the generation 
of GI symptoms. However, there is no consensus on whether infections from specific 
pathogens are linked to IBS.  
1.2.3 Current understanding of IBS pathophysiology  
Although the etiology of IBS is still poorly understood, there are extensive studies on the 
roles of central and peripheral mechanisms in IBS pathophysiology.(27–29) There is 
accumulating evidence suggesting the involvement of intestinal immunity, disordered gut-
brain communication, visceral hypersensitivity and dysbiosis in the generation of IBS 
symptoms in different individuals.(30,31) However, given the heterogeneity of IBS 
phenotypes and their different response rates to treatments, there may be no uniform 
mechanism for all IBS patients even when they share the same clinical manifestations.(30) In 
this section, some of the well-documented potential mechanisms and aetiological factors will 
be discussed in detail.  
Brain-gut axis: For a long time, IBS has been known as a brain-gut disorder as the central 
nervous system can influence GI functions (e.g., GI motility, intestinal permeability, immune 
activity, secretion, and microbiota composition) through the autonomic nervous system 
(ANS) and hypothalamic-pituitary-adrenal (HPA) axis. However, in about half of the IBS 
patients, their GI symptoms originate from the gut rather than the brain, as the psychological 
conditions occur after the diagnosis of IBS.(32) A gut-to-brain pathway is also supported by 
the fact that signal processing in the CNS can be affected by the use of probiotics.(33) Some 
of the above intestinal peripheral alterations may lead to the structural and functional changes 
in the brain, which further suggests a bi-directional regulatory network (Figure 4). Moreover, 
the brain plays a vital role in the central processing of interoceptive information from 
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peripheral sensory receptors. Some psychosocial disturbances may modify the normal way of 
central processing and amplify the sensory information (such as visceral pain). In a study 
testing coping model of catastrophizing in IBS patients, catastrophizing was found to be 
strongly associated with severity of pain syndrome.(34)  
 
FIGURE 4.  A schematic diagram to summarize the current understanding of IBS 
pathophysiology. Some key central and peripheral mechanisms, genetic and environmental 
factors are highlighted in IBS development.  
 
Psychological factors: Coexisting psychological conditions (particularly anxiety, and 
depression) have been well-documented to exacerbate IBS symptoms.(35,36) In IBS patients, 
a higher level of corticotropin releasing factor (CRF) was found to associate with excessive 
stress.(37) However, the therapeutic attempts of using CRF receptor antagonists failed in 
restoring colonic transits in female IBS-D patients.(38) Studies also suggest the association of 
early adverse life events (EALs) history with IBS susceptibility.(39) The imaging studies of 
the brain have shown associations of structural and functional alterations with EALs,(40) 
which can affect brain activities in IBS patients.(41) EALs have also been reported to affect 
gene expression regulation in brain via DNA methylation,(42–44) which may, together with 
alterations in brain networks, affect the risk of IBS development.     
Epithelial barrier: The intestinal epithelium serves as an interface for complex interactions 
between the intestinal environment, microbiota, and the gut mucosa. The mechanisms for gut 
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mucosal barrier dysfunction remain unknown, while many factors are considered to play a 
role including genetic variations, infections, altered microbiota composition, and food 
allergies.(45) Increased intestinal permeability has been known to be an important 
contributing factor to IBS, which could result in low-grade inflammation and altered immune 
activities in the intestinal mucosa.(45) Electron microscopic studies have identified enlarged 
epithelial cell spaces in gut mucosa biopsies from IBS-D patients.(46) Other structural defects 
of the gut barrier in IBS patients were also observed.(47) Besides, the role of tight junction 
proteins have been highlighted in increased intestinal permeability, the protein expression 
levels of zonula occludens-1 and occludin were found lower in IBS patients compared with 
controls.(48) A recent study has also demonstrated that miRNAs (miR-16 and miR-125b) can 
affect barrier function in IBS-D patients by regulating the expression of tight junction 
proteins claudin-2 and cingulin.(49)  
Altered immune response: Low-grade mucosal inflammation has been demonstrated to 
contribute to the generation of IBS symptoms from numerous studies.(50) Increased immune 
activities (such as increased inflammatory cells and levels of inflammatory markers) in the 
gut have been detected in IBS patients, pointing to an immune-mediated mechanism in at 
least subsets of IBS.(51) IBS-like symptoms can be manifested in around 33% of 
inflammatory bowel disease (IBD) patients in remission, which supports the role of the 
intestinal immunity in IBS pathophysiology.(52) However, negative results were obtained 
when testing the therapeutic effects of an anti-inflammatory agent (mesalazine) in IBS 
patients from two clinical trials.(53,54) Several studies have linked mast cells to the low-
grade immune activation in IBS, as higher amounts of mast cells and their mediators 
(protease, histamine) were found in colonic biopsies from IBS patients than control 
samples.(55,56) Moreover, IBS patients also showed higher serum levels of interleukin-6, 
interleukin-1-β and tumor necrosis factor-α (TNF-α) compared with healthy controls.(57) Of 
note, a recent study has highlighted the role of self-maintaining gut macrophages in intestinal 
homeostasis. Depletion of these macrophages may lead to several GI abnormalities including 
reduced intestinal motility and loss of enteric neurons, which further support the link of 
altered GI immune activities to the generation of IBS symptoms.(58)     
Bile acid malabsorption: Bile acids are substances synthesized in the liver and stored in the 
gallbladder, which are primarily responsible for digestion of fat in the small intestine. They 
recirculate between the liver and small intestine, and normally only a small portion will 
escape the circulation and enter the colon. Bile acids malabsorption (BAM) will result in 
excess amounts of bile acids entering the colon, and lead to GI symptoms.(59) A systematic 
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review reported a pooled prevalence of 28.1% (95% CI: 22.6–34%) for BAM in IBS-D.(60) 
Increased levels of serum C4 (7α-Hydroxy-4-cholesten-3-one, a product in bile acid 
synthesis) and fibroblast growth factor 19 (FGF19) have been linked to altered colonic transit 
time in IBS.(61,62) Also, genetic polymorphism in TGR5 (G-protein-coupled bile acid 
receptor 1) gene was shown to affect the regulation of colonic transit time in IBS-D 
patients.(63)  
Microbiota: The GI microbiota inhabits the entire digestive tract and includes around 400 
species. The commensal microbiota has a complex impact on human health, playing a vital 
role in the development of the intestinal immune system.(64,65) The gut microbiota 
composition is affected by many factors, above all, for instance diet and the use of 
antibiotics.(66,67) Although the associations between microbiota profiles and IBS have been 
extensively investigated and altered microbiota diversity has been highlighted,(65) the 
causative role of individual taxa and/or species is still unclear in IBS pathophysiology. 
Recent studies have shown significant differences in fecal microbiota composition between 
IBS patients and controls, and among IBS subtypes.(68–73) However, these studies were 
performed in small cohorts, and therefore require replication in independent larger surveys. 
Fecal samples are commonly used in microbiota researches as they are easily obtainable, but 
the location information is missing comparing with mucosal biopsies.  
1.2.4 Food components in IBS 
Dietary factors have been demonstrated to be involved in the development of IBS by several 
mechanisms. Firstly, the poorly absorbed components in the diet, particularly fermentable 
oligosaccharides, monosaccharides, disaccharides and polyols (FODMAPs), could result in 
GI symptoms due to their osmotic effect and colonic fermentation.(74) Secondly, some 
molecules in the food components (e.g., bioactive food molecules) and products from 
digestion may activate the receptors on GI tracts. These receptors include taste, nutrient, and 
fatty acids, and their activation will result in the release of various neurotransmitters and 
hormones affecting gut function. Studies also reveal that some food can activate mast cell 
directly and induce immune activities in the gut.(75) Last but not least, the interplays between 
diet and gut microbiota composition also play a vital role in IBS pathogenesis. Dietary 
changes have been reported to influence the gut microbial composition.(66) The dysbiosis in 
the gut can affect GI functions and involve in IBS pathogenesis in many ways, some of which 
have been discussed in Section 1.2.3. The complex network between the brain-gut axis and 
microbiota may be affected by diet-induced dysbiosis, and thus influence ENS function, gut 
motility, and sensation.(33)  
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Many IBS sufferers believe certain foods trigger their symptoms, and avoiding such foods is 
a common strategy they often self-implement.(76) Although food is complex and dietary 
components vary significantly from person to person, researchers have attempted to identify 
specific food components that induce GI symptoms. Once the role of any specific component 
in IBS pathogenesis is well clarified, dietary interventions can be designed to target certain 
subgroups of IBS patients. Several food components have been proposed to associate with 
IBS including carbohydrates, proteins and bioactive food chemicals.(74,77) Dietary proteins, 
especially gluten in wheat, may involve in the pathophysiology of IBS. Gluten has been 
implicated as the key contributing factor in celiac disease.(78) While nonceliac gluten 
sensitivity (NCGS) has also reported in other individuals and a gluten-free diet has shown to 
be beneficial for their IBS-like symptoms.(79)  
Latest researches have focused on poorly absorbed carbohydrates of relevance to IBS. 
Certain types of carbohydrates cannot be digested (oligosaccharides and non-starch 
polysaccharides) or slowly digested (fructose and polyols) in the small intestine. Moreover, 
the capability of carbohydrates digestion in GI tract could be affected by lack of hydrolases or 
reduced enzymatic activities, such as lactose intolerance caused by LCT (lactase) gene 
variations. Genetic variations in SI gene can result in congenital sucrase-isomaltase 
deficiency (CSID) which leads to malabsorption of sucrose and starch and a series of GI 
symptoms. The association of SI variants with IBS will be discussed in Section 1.3.1 and 
Paper I & II. The accumulation of all these mal-absorbed carbohydrates (FODMAPs) in the 
small intestine can cause increased water retention due to their osmotic effects.(80,81) 
Moreover, their colonic fermentation by gut microbiota may lead to overproduction of gas 
and the production of SCFAs. Both pain sensation and intestinal motility can be affected, 
leading to the generation of IBS symptoms.(82–84) An overview summarizing the role of 
FODMAPs in IBS pathogenesis is shown in Figure 5.  
Several strategies have been designed to target specific dietary alterations, such as lactose- or 
fructose-restricted diet. Their specific contents and nutritional risks have been summarized in 
a review article, there is lack of evidence for their long-term beneficial effects in IBS 
patients.(74) An Australian group has first proposed the low FODMAP diet in 2004 which 
recommends restricting intake of multiple mal-absorbed carbohydrates.(85) Since then, the 
supporting evidence for its benefits in IBS management has been accumulating and it has 
been recommended for IBS patients as a promising therapeutic approach.(86–88) There is 
evidence supporting that limiting dietary intake of FODMAPs helps the remission of 
symptoms in IBS patients.(89–91) 
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FIGURE 5. The description of FODMAPs contents and the proposed mechanism for their 
involvements in IBS pathogenesis. The schematic diagram which shows gut lumen on the top 
has been reused with permission from Staudacher HM. et al. Gut. 2017 Aug;66(8):1517-
1527. Copyright © 2017, BMJ Publishing Group Ltd.  
 
Moreover, a recent review article has shown that 50-80% of IBS patients benefit from low 
FODMAP diet for their GI symptoms.(92) A clinical trial has compared low FODMAP diet 
with modified guidance from the National Institute for Health and Care Excellence (mNICE) 
diet in IBS-D patients and reported a significantly higher symptom relief rate in low 
FODMAP diet treated group.(93) However, another study has reported no significant 
difference in the efficacy of IBS treatment between low FODMAP diet and other traditional 
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dietary practice.(94) There is also criticism for low FODMAP diet including potential 
deficiency of calcium intake(90) and altered microbiota composition in patients.(90,95) 
Further high-quality studies are warranted to validate the therapeutic effects of low FODMAP 
diet in IBS patients. 
1.2.5 Therapeutic intervention 
Multiple mechanisms have been implicated in IBS pathogenesis. The IBS phenotypes 
encompass subgroups with different predominant symptoms, the incomplete 
pathophysiological picture has added the difficulties in designing an overall therapeutic 
strategy that fits all IBS patients. So far, the therapeutic options for IBS have been limited, 
hampered by the poor understanding of IBS pathogenesis. Most of the interventions aim at 
remission of symptoms and sometimes may result in an unsatisfactory endpoint. An 
integrated management approach has been proposed, which incorporates diet, drugs, 
education, and psychotherapy.(96)   
Apart from the dietary intervention being discussed in Section 1.2.4, pharmacotherapy is 
usually applied to relieve GI symptoms in IBS (primarily altered intestinal transit time and 
visceral pain). The proposed pharmaceuticals for IBS cover a wide range of drug species, 
including antispasmodic drugs (e.g., dicyclomine),(97) intestinal motility accelerants (e.g., 
lubiprostone(98) and 5-HT4 receptor agonist prucalopride(99)), antidiarrheals (e.g., 
loperamide(100) and 5-HT3 receptor antagonists alosetron(101)), and probiotics.(102–104) 
Clinical trials have evaluated the efficacy of these drugs in IBS treatment. Many of them 
reported low quality of evidence, as summarized in a review article.(31)  
Genetic studies in IBS may open new gates for therapeutic interventions in at least a subset of 
IBS patients. The best example for their applications is in the candidate gene study of ion 
channel gene SCN5A (described in Section 1.3.1). It has been demonstrated that a chronic 
IBS-C female patient with a functional-damaging SCN5A mutation responded well with the 
administration of mexiletine, a compound known to rescue Nav 1.5 expression defects, as 
shown in Figure 6.  
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FIGURE 6. Treatment with mexiletine improved stool frequencies in an IBS-C patient 
carrying an SCN5A mutation. Complete spontaneous and small hard bowel movements are 
shown in dark and light grey shading, respectively. Reprinted with permission from Beyder et 
al., Gastroenterology. 2014 Jun; 146(7): 1659–1668. Copyright © 2014, Elsevier. 
 
1.3 GENETIC PREDISPOSITION TO IBS 
Genetic predisposition to IBS has been poorly investigated, although a heritable component 
has been demonstrated by a series of family and twin studies.(105–107) The heritability 
estimates of IBS reported from twin studies range from 0-57% (108–112) as described in 
Table 1. Despite the large variation, IBS heritability has been demonstrated in two large 
cohort twin studies (N=12,700 in Norway and N=16,961 in Sweden). 
 
TABLE 1. Summary of twin studies in IBS. 
Author 
(year) Cohort 
Number of study 












Norwegian Twin Study 12,700  48 
Lembo et al. 
(2007)(110) Minnesota Twin Study 986 22 




Swedish Twin Study 16,961 25 
 
Since the late 1980s, the epidemiological studies have demonstrated an increased risk of IBS 
among relatives of patients. The evidence of IBS familial aggregation is summarized in 
Table 2. Among them, the strongest evidence is shown in a large Swedish national study 
with more than 50,000 individuals where increased IBS risk has been found among first-, 
second- and third-degree relatives. Of note, a higher odd ratio for IBS was observed in closer 
kinship with IBS patients, e.g. an OR of 1.90 in parent, 1.27 in niece/nephew and 1.11 in 
cousins.(113)  
 
TABLE 2. Summary of familial aggregation studies in IBS. Reformulated from Makker, J. et 
al. (2015). Genetic epidemiology of irritable bowel syndrome. World J Gastroenterol. Oct 28, 
2015; 21(40): 11353-11361.(114) Copyright ©The Author(s) 2015. Creative Commons 









100 Family history of IBS has been detected in one-third of the studied IBS patients. 
Levy et al. 
(2000)(116) 631 
Children with IBS parents have more health care 
visits for their GI symptoms 
Locke et al. 
(2000)(24) 643 
Higher prevalence of IBS was reported in 
individuals whose first-degree relatives were with a 
history of bowel symptoms. 
Kalantar et al. 
(2003)(117) 355 
Relatives of IBS patients’ parents reported a higher 
IBS prevalence than relatives of IBS patients’ 
spouses. 
Saito et al. 
(2008)(118) 202 
Higher prevalence of IBS was observed in IBS 
patients’ relatives (21%) than controls (4%). 
Saito et al. 




51,952 The IBS risk is increased in first-, second- and even third-degree relatives.   
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It is believed that IBS is a complex genetic disorder with multiple factors being involved. The 
majority of IBS phenotypes may result from interactions between the genetic susceptibility 
background and environmental contributors. Moreover, IBS phenotypes may cover both 
complex genetic conditions and rare monogenic forms, and this implies different strategic 
approaches need to be adopted to identify causative factors in IBS genetic predisposition.   
1.3.1 Candidate gene approaches  
Numerous studies have explored the genetic predisposition to IBS in the past years, mostly 
based on candidate gene approaches and concentrating on single biological pathways such as 
serotonin signaling pathways due to the connection between the brain-gut axis and IBS.(120) 
Other genes involved in the control of intestinal immune activities, bile acid metabolism, and 
secretion have also been investigated. Some 60 genes or more have been tested over the years 
for their potential to contribute to the genetic predisposition of IBS and its clinical subtypes. 
However, these studies are mostly performed on small sample size and lacked replication in 
independent cohorts. Hence they may be of value from a historical perspective but poorly 
indicative of true genetic findings. The only exceptions may be represented by a few genes 
recently been reported by our research group to affect IBS risk across several independent 
cohorts such as NPSR1, TNFSF15, SCN5A, TRPM8, and SI.(121–126)  
NPSR1: NPSR1 encodes for neuropeptide S (NPS) receptor, which belongs to the G protein-
coupled receptor family. The NPSR1-NPS system is known to play a role in the HPA axis, 
modulating central signaling processing.(127) NPS-NPSR1 signaling pathway and NPSR1 
polymorphisms have been reported to be involved in the pathogenesis of a few conditions 
including asthma, IBD, rheumatoid arthritis, and panic disorders.(128–131) Our group has 
investigated NPSR1 polymorphism and its correlation with GI functions in IBS patients and 
identified several NPSR1 variants significantly associated with GI motility and 
sensation.(121) Physiological data from animal models were consistent with the findings that 
NPS receptors had noticeable effects on GI motility in mice.(132) Furthermore, another study 
from our group has demonstrated that NPSR1 polymorphisms also associated with recurrent 
abdominal pain in 1744 children from the Swedish birth cohort BAMSE.(124)  
TNFSF15: The TNFSF15 (tumor necrosis factor ligand superfamily member 15) gene was 
initially described as a genetic risk factor associated with Crohn's disease.(133) Its genetic 
polymorphisms were later found to be involved in the pathogenesis of other conditions 
including leprosy and spondyloarthritis.(134–136) In order to investigate the role of immune-
related genes and their polymorphisms in the pathophysiology of IBS,(51,137) our group has 
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selected 30 risk loci from Crohn's disease associations and tested their associations with IBS 
in two independent Swedish and American cohorts. Among all the variants, SNP rs4263839 
in the TNFSF15 gene was significantly associated with IBS risk (P=2.2×10−5), an even 
stronger signal was shown in individuals with constipation-predominant IBS (P 
=8.7×10−7).(122) These findings were later replicated by a UK study,(138) a study in a 
US/Canada cohort(139) and a meta-analysis,(140) suggesting TNFSF15 may be a true IBS 
genetic factor.  
SCN5A: Ion channels represent potential pathophysiologic and therapeutic targets in IBS 
because they are directly involved in both GI motility and visceral pain.(141) In collaboration 
with the Mayo Clinic, we tested the hypothesis that ion channelopathies might be involved in 
IBS pathophysiology by screening patients for SCN5A (Nav 1.5 voltage-dependent sodium 
channel) mutations. These mutations are often found in Brugada syndrome patients who 
report bowel symptoms more often than the general population.(123) The results showed that 
rare SCN5A mutations were present in 2.2% of IBS subjects from a cohort including 584 IBS 
patients and 1380 asymptomatic controls, and the majority of these (77%) were demonstrated 
to be functionally disruptive. Moreover, both common and rare variants in SCN5A gene were 
found to be associated with IBS risk in our IBS GWAS of a Swedish general population 
cohort(142) and tertiary IBS case-control cohorts from three European countries and the US, 
which further confirmed the correlations between SCN5A variants and IBS genetic 
predisposition. SCN5A findings support the notion that there may be subsets of IBS patients 
with rare genetic abnormalities, hence studies on these genetic variants may provide novel 
therapeutic targets and personalized treatment options for a subset of IBS phenotypes. More 
recently, another study has replicated the SCN5A findings in an IBS case-control cohort from 
US. SCN5A mutations were present in 2% of IBS patients (N=252) but none of the healthy 
controls (N=377).(143)  
TRPM8: In order to further explore the role of ion channel genes in IBS pathophysiology, we 
selected 27 ion channel genes contributing to GI motility and sensory function as additional 
candidates to affect IBS risk. Among these, nominal association signals were detected in our 
previous IBS GWAS(142) for four channels, namely the transient receptor potential channels 
TRPV3 and TRPM8, and the calcium voltage-gated channels CACNA1A and CACNA1E, 
which were selected for replication. In a Swedish multicenter study of Rome III defined IBS 
patients (N=386) together with asymptomatic healthy controls (N=357), several SNPs in the 
promoter region of TRPM8 gene showed significant replications. Furthermore, subtype 
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analyses revealed that TRPM8 SNPs affect IBS risk exclusively in the IBS-C patients, and 
correlate with harder stools in a general population sample.(125)  
Sucrase-isomaltase (SI): Congenital sucrase-isomaltase deficiency (CSID) is a rare genetic 
condition caused by malabsorption of carbohydrates. It is characterized primarily by diarrhea 
associated with bloating, gas and pain, which shares clinical symptoms with diarrhea-
predominant IBS forms. The SI enzyme is a disaccharidase that hydrolyzes sucrose (and 
starch) into glucose and fructose, and its functional defects lead to increased amounts of 
undigested carbohydrates in the colon, with luminal osmotic changes, fermentation and the 
generation of bowel symptoms and diarrhea. CSID manifestations vary in severity from 
patient to patient,(144) and CSID patients misdiagnosed with IBS have also been 
reported.(145,146) Hence, we hypothesized that SI dysfunctional polymorphisms may 
associate with IBS susceptibility, and tested four CSID mutations in three independent 
tertiary IBS case-control cohorts from Sweden, Italy, and the USA. We detected a suggestive 
association of carrying a CSID mutation with increased IBS risk (p=0.074, OR=1.84). In 
addition, we also demonstrated a relatively common variant in SI gene (rs9290264, 
p.Val15Phe) that was associated with reduced SI enzymatic activity in vitro. Its 15Phe variant 
was also linked to increased risks of IBS, especially IBS subtypes with diarrhea (IBS-D and 
IBS-M combined p=0.00012, OR=1.36). These findings may contribute to novel strategies 
for stratification and individualized treatment in IBS patients.(126) 
More recently, we have investigated the associations between the 15Phe variant of 
rs9290264, carbohydrate consumption and microbiota composition in two general population 
cohorts from Germany, PopGen (N=639) and FoCus (N=759).(147) The prevalence of IBS in 
15Phe carriers (3.69%) was significantly higher than in non-carriers (1.84%). After 
stratifying the individuals based on their daily consumption of starch, the strongest 
association between 15Phe and IBS susceptibility was detected in the group of individuals 
with low intake of daily starch (IBS prevalence 7.8% in carriers vs. 1.9% in non-carriers; 
P=0.029, OR=4.17). Moreover, the analysis of microbiota data from fecal samples of IBS 
patients reported an increased abundance of Blautia compared with controls (P=0.00035). 
After stratification by Val15Phe genotypes, we only observed the significantly increased 
abundance of Blautia in 15Phe-carrier IBS group (P=0.00041) but not in non-carriers. This 
study provides evidence that links the complex interaction between SI variants, carbohydrates 
intake and gut microbiota to IBS risk. 
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1.3.2 Genome-wide association studies for IBS  
Genome-wide association studies (GWAS) and their meta-analyses are powerful hypothesis-
free approaches for identifying polygenetic risk factors in complex disease.(148) Although 
the conventional methodology of GWAS has been well established, to date, very few GWAS 
efforts have been made to investigate IBS genetic predisposition. It is believed that the 
genetic susceptibility in the majority of IBS phenotypes is composed of a combination of 
genetic effects from low-penetrance common variants. Unequivocal IBS risk loci can thus 
only be identified through the analysis of exceptionally large sample sizes, likely coming 
from multinational global efforts.   
Recently, our group has proposed that a powerful approach to gene-hunting efforts in IBS 
may come from the study of general populations and biobank-scale samples exploiting the 
existing genotypic data and phenotypic information, resulting in a considerable gain in 
sample size and homogeneity.(107) Informative phenotypic data in the general population 
cohorts including Rome-criteria from questionnaires and International Classification of 
Diseases (ICD) codes from electronic medical records (EMR) can be applied to identify IBS 
cases and asymptomatic controls.   
The very first pilot IBS GWAS has been performed by our group on genotype data from 
5466 singletons (534 cases and 4932 controls) from the Swedish population-based Screening 
Across the Lifespan Twin (SALT) study, which includes questionnaires modules of 
gastrointestinal symptoms similar to Rome II criteria. Replication of findings confirmed 
evidence of a risk locus on chromosome 7p22.1 in 1,718 IBS cases and 1,793 healthy 
controls from 6 independent international cohorts.(142) This study provided 
experimental/methodological supports to our hypothesis that general population cohorts are 
ideal data sources for large-scale genetic studies in IBS.  
We then expanded the GWAS study in other four European population-based cohorts 
(LifeLines-DEEP, SHIP-Trend, TwinsUK, and NFBC1966) adapting the similar 
approach,(149) resulting in a total of 1335 IBS cases and 9768 controls in meta-analysis. We 
have identified seven additional genomic regions, mapping to 64 suggestive genes associated 
with IBS risk. Ion channel biology has been highlighted as a plausible pathway linked to IBS 
by functional annotation of all mapped genes. 
Despite previous GWAS efforts in IBS, so far, no genome-wide significant locus has been 
identified. It may be due to the limited statistical power of current studies. For example, to 
obtain a statistical power larger than 80%, around 10,000 cases and 10,000 controls are 
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needed to detect a genome-wide significant association (P<5.0×10-8) for a variant with 20% 
minor allele frequency (MAF) and genotype relative risk 1.15 (calculated by GAS Power 
Calculator, https://csg.sph.umich.edu/abecasis/gas_power_calculator/index.html). Powerful 
GWASs with an adequate sample size of IBS are expected to discover true unequivocal IBS 
risk factors. Meanwhile, clinically-relevant well-characterized IBS cases and controls are the 
most suitable material for validation and replication purposes in genetic studies. The large-
scale GWA studies with these samples will rely on international collaborations from 
multicenter studies.   
In summary, there are significant challenges in identifying IBS risk genes and variants. Given 
the heterogeneity of the IBS phenotype, various strategies may be necessary including 
candidate gene approaches and GWAS on large-scale cohorts to capture rare and common 
risk variants, respectively. Genetic research in IBS may contribute to the identification of 
pathophysiological mechanisms, a molecular re-classification of this condition, and hence 
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2 AIM OF THE THESIS 
2.1 OVERALL AIMS 
The overarching aim included in this thesis is to identify predisposing genes and risk variants 
of IBS and to characterize their functional roles. The ultimate goal of our IBS genetic studies 
is to identify important physiological pathways being involved in IBS pathogenesis, which 
will contribute to revealing novel targets for therapeutic development.  
2.2 SPECIFIC RESEARCH QUESTIONS 
In the first two studies of the thesis, we have adopted a candidate gene approach to further 
investigate the pathogenic role of functional variants of the SI gene in IBS patients. As 
described in Section 1.3.1, our previous study has demonstrated the significant associations 
between SI dysfunctional (hypomorphic) variants and increased risk of IBS. In this thesis, our 
further efforts were aimed at addressing the following research questions: 
 Is IBS risk affected also by hypomorphic SI variants other than rare CSID mutations? 
(Paper I) 
 Does SI genotype (hypomorphic variants carriership) affect the response to a low 
FODMAP diet in IBS patients? (Paper II) 
In the later large-scale studies, we have exploited a hypothesis-free GWAS approach to 
answer the research question:  
 Can true (genome-wide significant) IBS risk loci and genes be identified by applying 
large scale GWAS approaches in population-based and case-control cohorts? (Paper 
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3 MATERIALS AND METHODS 
The data source of all cohorts and detailed description of methodology in each study have 
been included in the constitute papers of the thesis. Figure 7 shows an overview of the 
research questions and the overall framework.  
 
FIGURE 7. A conceptual framework describing the research questions addressed by this 
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4 RESULTS AND DISCUSSION 
4.1 SI RARE PATHOGENIC VARIANTS AND IBS SUSCEPTIBILITY 
Mutations on the SI gene are reported to affect enzymatic activities and lead to congenital 
sucrase-isomaltase deﬁciency (CSID).(150,151) Given that CSID shares similar 
manifestations with IBS-D (primarily abdominal pain and diarrhea), some milder types of 
CSID can be misdiagnosed with IBS. In a recent study, we have investigated the pathogenic 
mechanism of SI functional variants in IBS symptom’s generation and demonstrated one 
common variant, as well as four mutations, are associated with increased risk of IBS.(126) In 
order to investigate the prevalence of other rare functional variants in IBS patients, we have 
implemented a two-step computational strategy in Paper I to first identify SI rare pathogenic 
variants (SI-RPVs) and then test their associations with IBS risk exploiting genotype data of 
2,207 IBS patients from multi-national tertiary centers.  
The working flow for SI-RPVs’ selection is summarized in a schematic diagram as shown in 
Figure 8.  
  
FIGURE 8. A schematic diagram to demonstrate the computational strategy and results of 
SI-RPVs’ selection. 
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A total 2,146 rare variants (MAF<1%) within the SI gene region were identified after 
screening the dbSNP database. Among them, 880 variants were predicted to be pathogenic 
based on their Mendelian Clinically Applicable Pathogenicity (M-CAP) and Combined 
Annotation-Dependent Depletion (CADD) scores. QCed genotype data was available for 46 
such variants in IBS patients. And 17 SI-RPVs could be tested based on the possibility of at 
least one IBS patients and available reference data from ancestry-matched The Exome 
Aggregation Consortium (ExAC).  
We identified 88 risk allele carriers out of 2207 IBS patients for the 17 selected SI-RPVs. A 
higher frequency was observed for most SI-RPVs when comparing IBS patients with the 
ExAC reference panel. And the cumulative χ2 test revealed that their overall prevalence in 
IBS patients (3.99%) is significantly higher than the controls (ancestry-matched ExAC 
reference population, P=0.00049, OR=1.45). Subtype stratified analyses in IBS patients 
showed consistent associations in IBS-C (prevalence 4.51%, P=0.0055, OR=1.65) and IBS-D 
(prevalence 4.20%, P=0.0045, OR=1.53).  
This study represents a significant follow-up to our previous work on SI functional variants in 
IBS patients,(126) in which the prevalence of 2.1% for the four most common CSID 
mutations was reported. We have detected a higher prevalence of SI-RPVs in a large group of 
tertiary IBS patients compared to reference allele frequencies from the general population, 
which further supports the association of SI rare and dysfunctional mutations with IBS 
susceptibility.  
The reference population from ExAC has been exploited as our source of controls, which 
constitutes one of the limitations in our study as these individuals were not screened for IBS 
symptoms. Given the high prevalence of IBS in the general population, there may be 
individuals with GI symptoms being included in the controls. However, a worse scenario, in 
this case, is a type II error, which would mean we underestimate the genetic risk of SI-RPVs 
in IBS patients.  
Furthermore, we also evaluated the genetic risk effect of other SI-RPVs without a risk allele 
carrier in IBS patients. One million times’ simulation has been run to randomly sample the 
reference population with the same size of IBS patients (N=2,207), and we have calculated 
the number of carriers for all 46 SI-RPVs in each simulation. Figure 9 shows the simulation 
results including the distribution of numbers of carriers in controls. We have observed a 
significantly low P-value (P=0.005713) for obtaining the same carriers’ number as in IBS 
patients (N=88) in control samples.   
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FIGURE 9. Distribution of the number of SI-RPVs carriers from one million simulations of 
sampling control population (N=2,207). The red line represents the number of SI-RPVs 
carriers in IBS patients (N=88). Reformulated from original work of Koldo Garcia 
Etxebarria. 
 
To sum up, our study has provided supporting evidence that carrying any of SI-RPVs could 
affect IBS susceptibility and lead to 45% higher odds of getting IBS than an ethnically 
matched reference population.  
4.2 SI GENOTYPE AFFECTS RESPONSE TO A LOW FODMAP DIET IN IBS 
PATIENTS 
The pathogenic role of SI functional variants in IBS susceptibility has been documented in 
previous studies and Paper I.(126) Carrying SI risk allele(s) could affect the function of SI 
enzyme, leading to accumulation of undigested sucrose and starch hydrolysis products 
(disaccharides) in the gut lumen, and their osmotic effect and fermentation may result in 
bowel symptoms (e.g., diarrhea, pain). These findings may contribute to better stratification 
of IBS patients based on their SI genotype for improved therapeutic strategies (e.g., specific 
dietary intervention). 
There may be potential nutrigenetic effects in terms of response to dietary intervention. 
Because a low FODMAP diet has been shown to exert beneficial effects in IBS patients, we 
elect to study SI genotype in relation to this therapeutic approach. Considering sucrose and 
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starch intakes are not restricted according to the standard low FODMAP diet, we hypothesize 
the individuals carrying effective SI variants would not benefit from a low FODMAP diet as 
much as non-carriers. To test our hypothesis, in Paper II we exploited the IBS-D cohort 
(N=85) which was included in a published clinical trial comparing the efficacy between low 
FODMAP and mNICE diets.(93)  
A similar strategy has been adopted as described in Paper I, we identified three SI-RPVs and 
the common SI variant Val15Phe (rs9290264) whose genotype data was available for IBS-D 
patients previously being included in a low FODMAP dietary intervention trial.  
IBS patients were treated with two different dietary interventions in the original study, low 
FODMAP diet (N=46) and mNICE diet (N=39). Their responses to dietary treatment were 
represented by overall symptom relief (≥50%) and pain response (≥30% reduction in 
abdominal pain score). We stratified the IBS patients according to their SI genotypes and 
performed an age/sex/BMI/Race-adjusted one-tailed logistic regression analysis to compare 
the endpoints between carriers and non-carriers.  
In low FODMAP diet-treated individuals, SI hypomorphic variants carriers reported a 
significant lower symptom relief rate than non-carriers (P=0.0308 and OR=4.66, Figure 10). 
Although no significant result was obtained in pain response, we observed a similar trend in 
the comparison (47.8% in carriers vs. 52.2% in non-carriers). We have also compared both 
endpoints in mNICE diet group, although the analyses showed no significant difference, 
lower response rates were detected in SI hypomorphic carriers compared with non-carriers 
from all comparisons. 
 
FIGURE 10. Symptom relief rates after treatment with low FODMAP diet in IBS-D patients 
stratified based on their genotypes of SI hypomorphic variants (carriers vs. non-carriers).  
  27 
 
To further explore whether the number of SI hypomorphic variants is also relevant to the 
response to low FODMAP diet (as carrying more SI hypomorphic variants may lead to a 
higher reduction of SI enzymatic activity), we stratified the IBS-D patients according to the 
number of SI hypomorphic variants they carried. The efficacy of the diet in terms of symptom 
relief and pain response was evaluated in three subgroups of IBS-D patients: double SI 
carriers based on the genotype of SI hypomorphic variants, single carriers and non-carriers. 
We first performed the analysis combining all IBS-D patients from two diet treatments (low 
FODMAP and mNICE), as shown in Figure 11, the age/sex/BMI/Race-adjusted one-tailed 
logistic regression analysis revealed a significant decrease of positive response rates to 
symptom relief as the SI hypomorphic copy numbers increase (P=0.0039). We also observed 
a similar trend in pain response although with a non-significant P-value (P=0.092).  
 
FIGURE 11. The associations between copy numbers of SI hypomorphic variants and 
response rate to endpoints (symptom relief and pain response) in all IBS-D patients 
combining two diet groups (low FODMAP and mNICE). Statistical analyses were performed 
by one-tailed logistic regression adjusting for gender, age, BMI and race groups. 
 
This study represents a significant step forward in the analysis of SI gene’s role in IBS 
management. The importance of carrying SI hypomorphic variants in relation to IBS risk 
have already been demonstrated in Paper I. Now Paper II also demonstrated that SI 
genotype can be informative when it comes to expected individual response to a low 
FODMAP diet. This opens up new lines of investigation, and it promises to provide 
opportunities for improving the efficacy and specificity of dietary interventions based on 
patients’ genotype (personalizing therapy). However, this study has been performed in a 
small cohort and the reduced SI enzymatic activities have not been validated in IBS-D 
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patients by biopsies and experimental measurements, follow-up studies with large sample 
size are warranted. 
In summary, we have shown that the efficacy of low FODMAP diet treatment was reduced in 
IBS patients carrying SI hypomorphic variants. Our findings suggest that screening for SI 
dysfunctional variants may be relative to inform patients’ stratification and improve the 
efficacy of dietary intervention in IBS patients.   
4.3 IBS RISK FACTORS IDENTIFIED VIA GWAS IN LARGE COHORTS 
We have discussed genetic predisposition to IBS in Section 1.3. Powered genetic studies with 
adequate sample size are lacking, and no genome-wide significant signal has been identified 
prior to this thesis. In Paper III and Paper IV, we explored IBS GWAS to identify genuine 
IBS risk factors through the analyses of large population-based and case-control cohorts.  
4.3.1 The female-specific IBS locus on chromosome 9q31.2 
UK Biobank (UKB) is a large population-based cohort from the UK with genotype data and 
rich phenotype information (demographics and health-related data) available for around 
500,000 individuals. In Paper III, we have exploited this resource for a GWAS comparing 
participants reporting a doctor's diagnosis of IBS with the remainder of the cohort. 
After quality control (QC) per sample and per marker, association analysis was performed on 
7,287,191 high-quality SNP markers from a total 9,576 IBS cases and 336,499 controls using 
logistic regression correcting for gender, age, genotyping array and top 10 PCs (principal 
components). We identified a genome-wide significant locus on chromosome 9q31.2 (tag 
SNP rs10512344, P=3.57×10-8) and 13 suggestive loci (P<5.0×10-6), harbouring a total of 93 
genes based on physical and regulatory elements mapping (Figure 12).  
Interestingly, the 9q31.2 locus was previously associated with age at menarche (AAM) in 
other GWASs.(152,153) Given the epidemiological evidence that IBS is more prevalent in 
females than males,(21) we further investigated the potential sex differences of the genetic 
effect of 9q31.2 association. Sex-stratified analysis showed a striking result, in that the 
9q31.2 finding appeared to be female-specific (rs10512344, P=4.29×10-10) and no association 
was found in the male subset (rs10512344, P=0.79) (Figure 12).  
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FIGURE 12. The Manhattan plot of IBS GWAS in UK Biobank and regional plots for the 
genome-wide significant locus 9q31.2 (all samples and sex-stratified). In the Manhattan plot, 
genome-wide significant (P=5.0×10-8) and suggestive (P=5.0×10-6) thresholds are shown by 
horizontal dashed lines (red and blue, respectively). Each suggestive locus (P<5.0×10-6) is 
highlighted and labelled by the closest gene mapped to the locus, and the number of 
additional mapped genes is shown in the following bracket. In the regional plots, the dash 
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lines represent the genome-wide significant threshold (P=5.0×10-8), and the color labels of 
each variant show their degrees of linkage disequilibrium (r2) with tag SNP rs10512344. 
Reprinted with permission from Paper III.(154) Copyright © 2018, Elsevier. 
The fact that 9q31.2 locus is associated with both AAM and female IBS raise the question of 
whether the associations are independent. A recent study in UKB demonstrated that early 
AAM is associated with IBS.(155) We applied three parallel approaches to address this 
question using full AAM summary statistics from a GWAS meta-analysis,(152) where 
rs10156597 is the most significant 9q31.2 marker associated with AAM (P=4.29×10-10, 
Beta=0.245). First, we performed a haplotype analysis combining rs10156597 and 
rs10512344 (tag SNP of IBS): the two markers show very low linkage disequilibrium 
(r2=0.04) and the haplotype was significantly associated with IBS only at the presence of risk 
allele “C” in rs10512344 (Figure 13A). Second, no reduction of the association signals was 
detected when conditioning on AAM (Figure 13B). Last, approximate Bayes factor 
colocalization analysis demonstrated that IBS and AAM were associated with 9q31.2 locus 
via different casual genetic risk factors (posterior probability H3=99.98%).  
To validate the female-specific findings in 9q31.2 locus, we further tested the association in 
independent follow-up cohorts, including a multi-national tertiary IBS case-control cohort 
(2045 cases and 7955 controls) and a Swedish Population-based colonoscopy study (Popcol, 
N=249). In line with the results in UKB, the significant association was replicated for tag 
SNP rs10512344 (P=0.015, Beta=0.383) in female IBS-C patients from case-control cohort. 
A consistent finding was also observed in females Popcol participants, as the risk allele C of 
rs10512344 was associated with harder stools. (P=0.0012, Beta=-1.105) There was no 
significant association in analyses of male samples from both follow-up cohorts.   
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FIGURE 13. Haplotype association and conditional analysis suggest IBS genetic effects in 
9q31.2 locus are independent of AAM. A. Summary statistics from haplotype association 
analysis between AAM and IBS tag SNPs. B. Regional plot of associations in 9q31.2 locus 
after conditioning on AAM summary statistics. The horizontal dash line represents the 
genome-wide significant threshold (P=5.0×10-8). Reprinted with permission from Paper 
III.(154) Copyright © 2018, Elsevier. 
 
In this study, we performed a GWAS of IBS in UKB cohort including 9,576 cases and 
336,499 controls, which is so far the only reasonable powered study to explore IBS genetics. 
We have identified the first genome-wide significant locus on chromosome 9q31.2, together 
with other 13 suggestive loci. The main strengths of this study include the large sample size, 
ideal replication materials (tertiary IBS case-control cohorts) and stringent QC pipeline on 
genotype data. While the IBS cases were defined by self-reported diagnosis in this study, the 
lack of direct clinical evidence constitutes the major limitation. Despite this, the application 
of self-reported traits enables us to gain a remarkable sample size for IBS genetic studies.  
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Our results have demonstrated that AAM and IBS associations are due to independent genetic 
effects, although both were located within 9q31.2 genomic region. Several traits have 
previously been linked to this locus including BMI, male’ voice breaking and waist 
circumference. Interestingly, sex hormones are known to play a key role in 
pathophysiological mechanisms of almost all these traits. Moreover, sex is also associated 
with different IBS prevalence, predominant clinical signs, and responses to 
treatment.(156,157) Females have been shown to report slower transit time than males as 
well as more frequent constipation episodes,(158,159) which is consistent with our results in 
follow-up replication analyses whether the risk allele of rs10512344 was associated with IBS-
C and harder stools. Sex hormones may be involved in the regulation of the brain-gut axis, 
affecting intestinal functions (motility, sensory, permeability, and immune activities) directly 
or through other hormones.(160,161) The GI symptoms in females have reported to vary 
according to the menstrual cycle.(160,162) Furthermore, exacerbated bowel symptoms have 
been observed in female IBS patients during their menstrual period compared with healthy 
controls.(163,164)  
Eight genes were mapped to the 9q31.2 locus based on chromatin interaction data. Among 
them, we proposed ELP1 (elongator complex protein 1, or IKBKAP) as the most likely 
causative gene within the locus. Autonomic dysfunction has been linked to IBS,(167) and 
mutations in the ELP1 gene, notably, lead to familial dysautonomia, an autonomic nervous 
system condition affecting the neuron’s development in sensory, sympathetic and 
parasympathetic nerves. Familial dysautonomia patients usually suffer from impaired pain 
sensitivity, altered intestinal motility, and temperature sensation.(165) Moreover, delayed 
AAM and premenstrual symptoms are often manifested in female familial dysautonomia 
patients.(166)  
4.3.2 Two genome-wide significant loci associated with IBS-D 
Well-characterized IBS patients diagnosed at specialized (neuro)gastroenterology clinics 
represent the best material to study IBS genetics and validate previous genetic findings linked 
to IBS. Individual cohorts from clinics are certainly underpowered for large-scale GWAS 
studies. Through multinational collaborations, our group has gathered IBS material from 
more than 20 tertiary centers from Europe and North America which enabled us to perform 
an unprecedented GWAS meta-analysis in tertiary IBS cases and controls (Paper IV). 
We have applied a robust GWAS pipeline to perform quality control and imputation on the 
original genotype data, resulting in 5,387,366 high-quality markers for 2,304 IBS cases and 
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14,614 controls from European pooled dataset, and 5,162,024 markers for 1,077 IBS cases 
and 10,502 controls from US dataset, respectively. The individual GWASs were carried out 
via a linear mixed model adjusting for sex, age and top 10 PCs, followed by the Z-score 
based meta-analysis.      
The meta-analyses results revealed a total of 38 suggestive loci linked to IBS and its 
subtypes. Two genome-wide significant loci were identified in IBS-D meta-analysis, one on 
chromosome 9p21 (tag SNP rs10970019, P=4.9×10-8) and the other on 19q13.11 (tag SNP 
rs1260633, P=4.1×10-8). Of note, the most significant locus on chromosome 6q21 in IBS-C 
meta-analysis also showed an association close to genome-wide significance (tag SNP 
rs74742584, P=5.69×10-8). The Manhattan plots of GWAS meta-analyses are shown in 
Figure 14.  
 
FIGURE 14. Manhattan plots summarizing GWAS meta-analyses results of IBS and each 
subtype. Genome-wide significant (P=5.0×10-8) and suggestive (P=5.0×10-6) thresholds are 
shown by horizontal lines (red and blue, respectively). Genome-wide significant loci are 
highlighted as red and bold. The closest mapping gene to the lead SNP is reported for each 
association signal, the number of additional mapped genes from the same locus is shown in 
brackets. 
 
Functional annotation (via FUMA) of identified suggestive loci mapped 138 genes via 
physical locations and regulatory elements (eQTL and chromatin interaction) in meta-
analysis of IBS-ALL (and 108 genes in IBS-C, 72 in IBS-D, 131 in IBS-M respectively). 
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Gene-sets enrichment analyses highlighted several pathways associated with IBS or their 
subgroups, including ion channel activities (IBS-C & IBS-M). A summary of significantly 
enriched pathways from each meta-analysis is presented in Figure 15. The most significant 
enriched pathways were from IBS-C meta-analysis, including sensory perception of chemical 
stimulus (adjusted P=2.02×10-14), olfactory receptor activity (adjusted P=1.31×10-11) and G 
protein coupled receptor activity (adjusted P=2.82×10-9). 
 
FIGURE 15. Significant findings in gene-sets enrichment analyses by mapping genes from 
each IBS meta-analyses (all samples and each subtype). 
 
The genome-wide significant loci in IBS-D meta-analysis have not been previously 
described. LSM14A (MRNA Processing Body Assembly Factor) gene was physically mapped 
to locus 19q13.11. Other 19 genes were mapped to the same locus via their associations with 
eQTL or chromatin interaction. The tag SNP rs10970019 for another genome-wide 
significant locus 9p21 was located at an intergenic region. Thus no physical mapping gene 
was identified. LINGO2, ACO1, NDUFB6, and GVQW1 genes were mapped via regulatory 
elements. The near genome-wide significant locus 6q21 associated with IBS-C contained six 
mapped genes (MARCKS, TUBE1, WISP3, LAMA4, RFPL4B, and FAM229B). In order to 
gain insight into the putative biology and align these associations, we searched the GWAS 
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Catalog and other repositories for evidence or associations of these genes with other 
conditions (PheWAS). The results are summarized in Figure 16, candidate genes who were 
mostly associated also to metabolic, immunological and psychiatric domains.   
 
FIGURE 16. PheWAS associations of top significant loci and their mapped genes in IBS 
meta-analyses. Only the genome-wide significant associations (P<5.0×10-8) are shown. N 
represents the sample size of each publish GWAS.  
 
As this is the largest case-control genetic study of IBS so far, we sought to assess previously 
reported associations in our GWAS meta-analyses. Out of the 15 tested genes, some evidence 
of replication was detected for 12 genes including TNFSF15, NPSR1, SI (Paper I & II), 
SCN5A and KDELR2/GRID2IP locus. The female-specific locus 9q31.2 being highlighted in 
Paper III was also investigated in this study via sex-stratified meta-analyses. We observed a 
similar trend for the tag SNP rs10512344, as a significant association was detected in female 
IBS-C meta-analysis (P=0.034), but not in analysis with male IBS-C patients (P=0.25).  This 
finding is as expected given that the majority of tertiary IBS case-control samples have 
already been exploited as replication material in Paper III.   
These GWAS meta-analyses represent the current largest efforts in the study of IBS 
susceptibility in well-characterized tertiary IBS patients, including a total 3,381 IBS cases and 
25,116 controls. Different from our GWAS study in Paper III focusing on self-reported IBS 
(lack of direct clinical diagnoses), this study aims to capture IBS genetic risks exploiting 
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smaller numbers but well-characterized IBS phenotypes. A robust GWAS pipeline has been 
implemented on the multinational data sources to control for potential population 
stratifications including using the linear mixed model in the association tests. Among the 
limitations of the study, it is the fact that controls samples have not been recruited at the same 
sites as cases and IBS symptoms were not screened. 
Two novel genome-wide significant loci have been identified to associate with IBS-D, the tag 
SNP rs1260633 of locus 19q13.11 is situated in gene LSM14A, which encodes molecules as a 
component of the mRNA processing body (P-body). LSM14A has been reported to be 
involved in antiviral responses and IFN pathways.(168) Of note, LSM14A is also associated 
with chronic inflammatory diseases (including Crohn’s disease and Ulcerative colitis),(169) 
which suggests it may contribute to GI symptoms by disturbing antiviral immune activities in 
the gut. No physical mapping gene has been identified for the other locus 9p21. Interestingly, 
genes mapped to this locus based on chromatin-interactions have been reported to associate 
with immune activities (NDUFB6, ACO1) and neuroticism (LINGO2). This finding is 
noteworthy as neuroticism has been demonstrated to be psychiatric comorbidity of IBS and 
affect IBS risk.(170–172) PheWAS results including all genes mapped to genome-wide 
significant loci indicate that they may contribute to the generation of IBS symptoms via 
altered metabolic and immune activities, and/or psychiatric conditions. 
This study also provides initial evidence of the genetic differences among IBS subtypes. The 
association patterns from meta-analyses results are entirely different between IBS-C and IBS-
D, with no shared identified risk loci or mapped genes. The downstream functional 
annotation also suggests different biological pathways in the two IBS subtypes. Ion channel 
activities have been significantly enriched with IBS-C mapped genes. Instead, PheWAS 
results have linked disordered metabolic and immune activities to IBS-D. These findings may 
help elucidate pathophysiological mechanisms among IBS subtypes. 
4.3.3 Ion channel activities as plausible pathways contributing to IBS risk  
One of the most striking results to emerge is that ion channel pathways have been highlighted 
in gene-sets enrichment analyses from both Paper III & IV.  Ion channels are membrane 
proteins presenting in all excitable cells that respond to signals and control ion flows across 
the cell membrane. These proteins are widely expressed across the gut, particularly in 
interstitial cells of Cajal (ICCs) and smooth muscle cells (SMCs), playing vital roles in 
controlling intestinal motility, sensation and fluid secretion.(141,173) Mutations of ion 
  37 
channel genes may lead to malfunctions of these transmembrane molecules (channelopathies) 
and contribute to the IBS pathogenesis.(174)  
The role of genetic variations in ion channel genes in IBS susceptibility is discussed in 
Section 1.3.1, in which genetic polymorphism in SCN5A and TRPM8 have been 
demonstrated to associate with IBS risk. Remarkably, there is additional evidence supporting 
the role of ion channel activities in IBS pathophysiology including the results from the two 
previous GWAS and meta-analyses of Rome criteria defined IBS(149) and stool 
frequency(175), respectively. Our results further support these observations, highlight the link 
of ion channel activities to IBS pathophysiology, and pinpoint genes being involved in ion 
channel activities (CLCA1, CLCA2, CLCA4, ANO3, TRPA1, CNGA4, KCNK2, and 
KCNMB2) as important candidates warranting independent follow-ups.  
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5 CONCLUDING REMARKS 
This thesis contributes to improving our understanding of genetic predisposition to IBS and 
adds new knowledge to IBS pathophysiology. In these genetic studies, we have evaluated and 
validated some predisposing genes and risk variants linked to IBS susceptibility, and 
identified some novel IBS risk factors warranting further investigation.   
Back to the specific research questions in Section 2.2, this thesis attempts to provide 
preliminary answers: 
Is IBS risk affected also by hypomorphic SI variants other than rare CSID mutations? 
In Paper I, after screening the genotypes of SI-RPVs in 2207 tertiary IBS patients, we have 
observed a prevalence 3.99% of SI-RPVs in all IBS patients (and 4.51% in IBS-C, 4.20% in 
IBS-D respectively), which are significantly higher than the reference population (2.78 % in 
ExAC). The odds of getting IBS is 45% higher in SI-RPVs carriers than non-carriers.  
Does SI genotype (hypomorphic variants carriership) affect the response to a low 
FODMAP diet in IBS patients? 
Paper II has evaluated the response rates in a group of IBS-D patients treated with low 
FODMAP or mNICE diet after stratification based on genotype data for SI hypomorphic 
variants. Our results have demonstrated that carrying SI hypomorphic variants reduces by 3-4 
folds the chances of benefiting from a low FODMAP diet. 
Can true (genome-wide significant) IBS risk loci and genes be identified by applying 
large scale GWAS approaches in population-based and case-control cohorts? 
We have exploited a population-based cohort in the UK in Paper III and multi-national 
tertiary IBS cases and controls in Paper IV to study IBS genetics.  
In Paper III, we have identified a female-specific genome-wide significant association at 
chromosome 9q31.2. This finding has been consolidated by the replication evidence in 
tertiary IBS case-control cohorts and a Swedish population-based cohort (Popcol). Two more 
genome-wide association loci have been detected in Paper IV from the IBS-D meta-analysis 
combining European and US datasets. Of note, the ion channel activities have been 
highlighted in both studies from the gene-sets enrichment analyses, which is in line with a 
series of our previous findings that link ion channel biology to IBS. Follow-up studies in 
independent cohorts are needed to confirm these findings and clarify their biological 
mechanisms in IBS pathophysiology.   
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Additionally, Paper III and Paper IV have also addressed the following research questions: 
Are there sex-specific genetic effects in IBS?  
The sex-stratified analyses of the genome-wide significant locus 9q31.2 in Paper III revealed 
that the association was absent in males and entirely derived from the female group. This 
female-specific locus may be involved in IBS pathogenesis via the action of sex hormones, 
which could partially account for the different IBS prevalence and clinical manifestations 
between female and male groups.  
Are there different genetic characteristics of IBS subtypes? 
In Paper IV, we have provided preliminary evidence for the genetic comparisons between 
IBS-C and IBS-D. No common suggestive locus or mapped gene was identified from the 
tertiary IBS GWAS meta-analyses. Moreover, functional annotation of their GWAS results 
has highlighted different biological pathways, suggesting different genetic architecture and 
underlying molecular mechanisms in the two IBS subgroups.  
Are previously reported IBS associations confirmed in larger scale GWAS studies? 
We have inspected the association signals for previously reported IBS risk genes and loci in 
Paper IV. 12 out of 15 tested genes have been validated in the GWAS meta-analyses 
exploiting tertiary IBS cases and controls including TNFSF15, NPSR1, SI, SCN5A, and 
KDELR2/GRID2IP locus. The supporting evidence may help prioritize candidate genes for 
investigating their causative role in IBS pathophysiology.  
To sum up, this thesis has validated the role of SI functional variants in IBS susceptibility and 
identified new genetic factors predisposing to IBS. These results may contribute to the 
identification of pathophysiological mechanisms that can help explain the etiology of IBS and 
may ultimately provide novel therapeutic targets.  
The current definition of IBS may correspond to a constellation of various conditions. Even 
within the same IBS phenotype, the underlying molecular mechanism can vary significantly 
from patient to patient. Our genetic studies may contribute to a better classification system for 
IBS patients in two ways. On the one hand, for a small subset of IBS patients, their GI 
symptoms may be accounted for by the dysfunctional variations in single genes, such as 
channelopathies (SCN5A, TRPM8) and carbohydrate malabsorption (SI). These “organic” 
conditions can be treated with specific interventions including ion channel blockers for 
channelopathies or dietary intervention for carbohydrate malabsorption (one successful 
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example of channelopathies treatment has already been discussed in Section 1.2.5). On the 
other hand, the majority of IBS phenotypes result from the interactions between 
environmental factors and the polygenetic background. Large-scale genetic studies are 
powerful tools to capture their polygenetic risk factors, contributing to a better stratification 
of IBS patients based on their polygenic risk scores (PRS) and pathways from biological 
annotations. Figure 17 shows the application of two genetic approaches in re-classification 
and designing personal therapeutic strategies for IBS patients.  
 
FIGURE 17. Potential interpretation of genetic information (obtained in this thesis and 
elsewhere) for patients stratification and precision medicine in IBS. Original work designed 
by Mauro D’Amato, reformulated and print with permission.   
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